Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Hayato Kawachi

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

H. Kawachi1, M. Tamiya1, A. Tamiya2, S. Ishii2, K. Hirano3, H. Matsumoto3, T. Yokoyama4, T. Ishida5, K. Ryota6, D. Fujimoto7, K. Hosoya7, H. Suzuki8, T. Hirashima9, M. Kanazu10, N. Sawa11, J. Uchida12, M. Morita13, T. Makio14, S. Hara14, T. Kumagai1

Author affiliations

  • 1 Thoracic Oncology, Osaka International Cancer Instisute, 541-8567 - Osaka/JP
  • 2 Internal Medicine, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 3 Department Of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, 660-8550 - Amagasaki/JP
  • 4 Department Of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki/JP
  • 5 Department Of Respiratory Medicine, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 6 Respiratory Medicine, Himeji Medical Center, 670-8520 - Himeji/JP
  • 7 Respiratory Medicine, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 8 Thoracic Oncology, Osaka Habikino Medical Center, 583-8588 - Habikino/JP
  • 9 Thoracic Oncology, Osaka Prefectural Habikino Hospital, 583-8588 - Habikino/JP
  • 10 Department Of Thoracic Oncology, Osaka Toneyama Medical Center, 560-0045 - Toyonaka/JP
  • 11 Department Of Thoracic Oncology, Toneyama National Hospital, 560-0045 - Toyonaka/JP
  • 12 Respiratory Medicine, Osaka General Medical Center, 558-8558 - Osaka/JP
  • 13 Respiratory Medicine, Kobe City Medical Center West Hospital, 653-0013 - Kobe/JP
  • 14 Respiratory Medicine, Itami City Hospital, 664-8540 - Itami/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2170

Background

Little is known about the associations between treatment outcome for immune checkpoint inhibitors and metastatic sites in patients with advanced non-small cell lung cancer (NSCLC). Furthermore, these previous studies included patients irrespective of their PD-L1 status and treatment lines. Therefore, we conducted a multicentered retrospective study to investigate the predictive factors of metastatic sites as first-line pembrolizumab efficacy in patients with PD-L1 tumor proportion score (TPS) ≥50% advanced NSCLC.

Methods

We retrospectively analyzed patients with advanced NSCLC and PD-L1 TPS ≥ 50% who received pembrolizumab as the first-line therapy at 11 institutions between February 2017 and April 2018. Clinical data including metastatic sites at the time of administering pembrolizumab treatment were collected. Treatment outcome of pembrolizumab was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.

Results

In total, 213 patients were included in the study. The median age was 71 years (range 39-91). Of the 213 patients, 176 (83%) were men, 172 (81%) had Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1. The major metastatic sites were thoracic lymph nodes metastasis (77%), intrapulmonary metastasis (31%), bone metastasis (28%), and malignant pleural effusion (26%). In multivariate analysis, poor PS (hazard ratio: 1.82, 95.0% confidence interval: 1.15–2.30; P = 0.046) and malignant pleural effusion (hazard ratio: 1.52, 95.0% confidence interval: 1.01–2.30; P = 0.046) was identified as an independent predictor of shorter progression free survival in patients treated with pembrolizumab.

Conclusions

In patients with advanced NSCLC and PD-L1 TPS ≥50% who received first-line pembrolizumab, poor PS and malignant pleural effusion are independent predictors of pembrolizumab efficacy.

Clinical trial identification

UMIN000032470.

Editorial acknowledgement

Legal entity responsible for the study

Hanshin Oncology clinical Problem Evaluation group (HOPE).

Funding

Has not received any funding.

Disclosure

H. Kawachi: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. M. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. A. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. K. Hirano: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Yokoyama: Honoraria (self): Taiho Pharmaceutical Co., Ltd. T. Ishida: Honoraria (self): Merck Sharp & Dohme, Corp. D. Fujimoto: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Hirashima: Honoraria (self): Taiho Pharmaceutical Co., Ltd. M. Kanazu: Honoraria (self): Merck Sharp & Dohme, Corp. T. Kumagai: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.